본문 바로가기
KERD
논문KCI 등재

Host-microbial Cross-talk in Inflammatory Bowel Disease

Hiroko Nagao-Kitamoto|Nobuhiko Kamada
대한면역학회 (The Korean Association of Immunologists)|2017.02|Immune Network|제17권 제1호|pp. 1-12|DOI https://doi.org/10.4110/in.2017.17.1.1

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

Inflammatory bowel diseaseDysbiosisGut microbiotaPathobiont

초록

A vast community of commensal microorganisms, commonly referred to as the gut microbiota, colonizes the gastrointestinal tract (GI). The involvement of the gut microbiota in the maintenance of the gut ecosystem is two-fold: it educates host immune cells and protects the host from pathogens. However, when healthy microbial composition and function are disrupted (dysbiosis), the dysbiotic gut microbiota can trigger the initiation and development of various GI diseases, including inflammatory bowel disease (IBD). IBD, primarily includes ulcerative colitis (UC) and Crohn's disease (CD), is a major global public health problem affecting over 1 million patients in the United States alone. Accumulating evidence suggests that various environmental and genetic factors contribute to the pathogenesis of IBD. In particular, the gut microbiota is a key factor associated with the triggering and presentation of disease. Gut dysbiosis in patients with IBD is defined as a reduction of beneficial commensal bacteria and an enrichment of potentially harmful commensal bacteria (pathobionts). However, as of now it is largely unknown whether gut dysbiosis is a cause or a consequence of IBD. Recent technological advances have made it possible to address this question and investigate the functional impact of dysbiotic microbiota on IBD. In this review, we will discuss the recent advances in the field, focusing on host-microbial cross-talk in IBD.

Abstract

A vast community of commensal microorganisms, commonly referred to as the gut microbiota, colonizes the gastrointestinal tract (GI). The involvement of the gut microbiota in the maintenance of the gut ecosystem is two-fold: it educates host immune cells and protects the host from pathogens. However, when healthy microbial composition and function are disrupted (dysbiosis), the dysbiotic gut microbiota can trigger the initiation and development of various GI diseases, including inflammatory bowel disease (IBD). IBD, primarily includes ulcerative colitis (UC) and Crohn's disease (CD), is a major global public health problem affecting over 1 million patients in the United States alone. Accumulating evidence suggests that various environmental and genetic factors contribute to the pathogenesis of IBD. In particular, the gut microbiota is a key factor associated with the triggering and presentation of disease. Gut dysbiosis in patients with IBD is defined as a reduction of beneficial commensal bacteria and an enrichment of potentially harmful commensal bacteria (pathobionts). However, as of now it is largely unknown whether gut dysbiosis is a cause or a consequence of IBD. Recent technological advances have made it possible to address this question and investigate the functional impact of dysbiotic microbiota on IBD. In this review, we will discuss the recent advances in the field, focusing on host-microbial cross-talk in IBD.

참고문헌 (99)

  1. Kamada, N., "Regulation of the immune system by the resident intestinal bacteria", Gastroenterology, 146, pp.1477~1488 (2014)
  2. Honda, K., "The microbiota in adaptive immune homeostasis and disease", Nature, 535, pp.75~84 (2016)
  3. Thaiss, C. A., "The microbiome and innate immunity", Nature, 535, pp.65~74 (2016)
  4. Kamada, N., "Control of pathogens and pathobionts by the gut microbiota", Nat. Immunol, 14, pp.685~690 (2013)
  5. Kamada, N., "Role of the gut microbiota in immunity and inflammatory disease", Nat. Rev. Immunol, 13, pp.321~335 (2013)
  6. Hiroko Nagao-Kitamoto, "Pathogenic role of the gut microbiota in gastrointestinal diseases", Intestinal research, 14(2), pp.127~138 (2016), 대한장연구학회
  7. Rooks, M. G., "Gut microbiota, metabolites and host immunity", Nat. Rev. Immunol, 16, pp.341~352 (2016)
  8. Sonnenburg, J. L., "Diet-microbiota interactions as moderators of human metabolism", Nature, 535, pp.56~64 (2016)
  9. Lee, W. J., "Gut microbiota-generated metabolites in animal health and disease", Nat. Chem. Biol, 10, pp.416~424 (2014)
  10. Manichanh, C., "The gut microbiota in IBD", Nat. Rev. Gastroenterol. Hepatol, 9, pp.599~608 (2012)
  11. Nell, S., "The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models", Nat. Rev. Microbiol, 8, pp.564~577 (2010)
  12. Frank, D. N., "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases", Proc. Natl. Acad. Sci. U. S. A, 104, pp.13780~13785 (2007)
  13. Gophna, U., "Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis", J. Clin. Microbiol, 44, pp.4136~4141 (2006)
  14. Kang, S., "Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray", Inflamm. Bowel Dis, 16, pp.2034~2042 (2010)
  15. Joossens, M., "Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives", Gut, 60, pp.631~637 (2011)
  16. Sokol, H., "Specificities of the fecal microbiota in inflammatory bowel disease", Inflamm. Bowel Dis, 12, pp.106~111 (2006)
  17. Vigsnaes, L. K., "Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus", Sci. Rep, 3, pp.1110~ (2013)
  18. Sokol, H., "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", Proc. Natl. Acad. Sci. U. S. A, 105, pp.16731~16736 (2008)
  19. Sokol, H., "Low counts of Faecalibacterium prausnitzii in colitis microbiota", Inflamm. Bowel Dis, 15, pp.1183~1189 (2009)
  20. Morgan, X. C., "Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment", Genome Biol, 13, pp.R79~ (2012)
  21. Machiels, K., "A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis", Gut, 63, pp.1275~1283 (2014)
  22. Barcenilla, A., "Phylogenetic relationships of butyrate-producing bacteria from the human gut", Appl. Environ. Microbiol, 66, pp.1654~1661 (2000)
  23. Lopez-Siles, M., "Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth", Appl. Environ. Microbiol, 78, pp.420~428 (2012)
  24. Furusawa, Y., "Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells", Nature, 504, pp.446~450 (2013)
  25. Smith, P. M., "The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis", Science, 341, pp.569~573 (2013)
  26. Zhang, M., "Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats", BMC Gastroenterol, 16, pp.84~ (2016)
  27. Downes, J., "Dialister invisus sp. nov., isolated from the human oral cavity", Int. J. Syst. Evol. Microbiol, 53, pp.1937~1940 (2003)
  28. Miller, T. L., "Bioconversion of cellulose to acetate with pure cultures of Ruminococcus albus and a hydrogen-using acetogen", Appl. Environ. Microbiol, 61, pp.3832~3835 (1995)
  29. Duncan, S. H., "Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine", Appl. Environ. Microbiol, 68, pp.5186~5190 (2002)
  30. Flint, H. J., "Polysaccharide utilization by gut bacteria:potential for new insights from genomic analysis", Nat. Rev. Microbiol, 6, pp.121~131 (2008)
  31. Leitch, E. C., "Selective colonization of insoluble substrates by human faecal bacteria", Environ. Microbiol, 9, pp.667~679 (2007)
  32. Mukherjee, P. K., "Mycobiota in gastrointestinal diseases", Nat. Rev. Gastroenterol. Hepatol, 12, pp.77~87 (2015)
  33. Rautava, S., "Microbial contact during pregnancy, intestinal colonization and human disease", Nat. Rev. Gastroenterol. Hepatol, 9, pp.565~576 (2012)
  34. Shaw, S. Y., "Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease", Am. J. Gastroenterol, 105, pp.2687~2692 (2010)
  35. Kronman, M. P., "Antibiotic exposure and IBD development among children: a population-based cohort study", Pediatrics, 130, pp.e794~e803 (2012)
  36. Pompei, A., "Folate production by bifidobacteria as a potential probiotic property", Appl. Environ. Microbiol, 73, pp.179~185 (2007)
  37. Biasco, G., "Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis", Cancer Epidemiol. Biomarkers Prev, 6, pp.469~471 (1997)
  38. Kinoshita, M., "Dietary folic acid promotes survival of Foxp3+ regulatory T cells in the colon", J. Immunol, 189, pp.2869~2878 (2012)
  39. Wexler, H. M., "Bacteroides: the good, the bad, and the nitty-gritty", Clin. Microbiol. Rev, 20, pp.593~621 (2007)
  40. Round, J. L., "The gut microbiota shapes intestinal immune responses during health and disease", Nat. Rev. Immunol, 9, pp.313~323 (2009)
  41. Mazmanian, S. K., "A microbial symbiosis factor prevents intestinal inflammatory disease", Nature, 453, pp.620~625 (2008)
  42. Mazmanian, S. K., "An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system", Cell, 122, pp.107~118 (2005)
  43. Waidmann, M., "Bacteroides vulgatus protects against Escherichia coliinduced colitis in gnotobiotic interleukin-2-deficient mice", Gastroenterology, 125, pp.162~177 (2003)
  44. Rehman, A., "Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients", J. Med. Microbiol, 59, pp.1114~1122 (2010)
  45. Baumgart, M., "Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum", ISME J, 1, pp.403~418 (2007)
  46. Lapaquette, P., "Crohn's disease-associated adherentinvasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly", Cell Microbiol, 12, pp.99~113 (2010)
  47. Mukhopadhya, I., "IBD-what role do Proteobacteria play?", Nat. Rev. Gastroenterol. Hepatol, 9, pp.219~230 (2012)
  48. Boudeau, J., "Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease", Infect. Immun, 67, pp.4499~4509 (1999)
  49. Darfeuille-Michaud, A., "High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease", Gastroenterology, 127, pp.412~421 (2004)
  50. Barnich, N., "CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease", J. Clin. Invest, 117, pp.1566~1574 (2007)
  51. Arthur, J. C., "Intestinal inflammation targets cancer-inducing activity of the microbiota", Science, 338, pp.120~123 (2012)
  52. Nougayrede, J. P., "Escherichia coli induces DNA double-strand breaks in eukaryotic cells", Science, 313, pp.848~851 (2006)
  53. Cuevas-Ramos, G., "Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells", Proc. Natl. Acad. Sci. U. S. A, 107, pp.11537~11542 (2010)
  54. Itzkowitz, S. H., "Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease", Inflamm. Bowel Dis, 11, pp.314~321 (2005)
  55. Kornbluth, A., "Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee", Am. J. Gastroenterol, 105, pp.501~523 (2010)
  56. Horing, E., "Frequency and spectrum of microorganisms isolated from biopsy specimens in chronic colitis", Endoscopy, 23, pp.325~327 (1991)
  57. Plessier, A., "Intercurrent Klebsiella oxytoca colitis in a patient with Crohn's disease", Gastroenterol. Clin. Biol, 26, pp.799~800 (2002)
  58. Wagner, J., "Identification and characterisation of Pseudomonas 16S ribosomal DNA from ileal biopsies of children with Crohn's disease", PLoS One, 3, pp.e3578~ (2008)
  59. Garrett, W. S., "Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis", Cell Host Microbe, 8, pp.292~300 (2010)
  60. Deng, Q., "Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins", Annu. Rev. Microbiol, 62, pp.271~288 (2008)
  61. Ruby, T., "Salmonella's long-term relationship with its host", FEMS Microbiol. Rev, 36, pp.600~615 (2012)
  62. Geddes, K., "Nod1 and Nod2 regulation of inflammation in the Salmonella colitis model", Infect. Immun, 78, pp.5107~5115 (2010)
  63. Hugot, J. P., "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease", Nature, 411, pp.599~603 (2001)
  64. Verma, R., "Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India", J. Clin. Microbiol, 48, pp.4279~4282 (2010)
  65. Duffy, M., "Sulfatereducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis", Dis. Colon Rectum, 45, pp.384~388 (2002)
  66. Pitcher, M. C., "Hydrogen sulphide : a bacterial toxin in ulcerative colitis?", Gut, 39, pp.1~4 (1996)
  67. Loubinoux, J., "Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases", FEMS Microbiol. Ecol, 40, pp.107~112 (2002)
  68. Muyzer, G., "The ecology and biotechnology of sulphate-reducing bacteria", Nat. Rev. Microbiol, 6, pp.441~454 (2008)
  69. Devkota, S., "Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-", -mice, 2012, pp.487, 104~108
  70. Rowan, F., "Desulfovibrio bacterial species are increased in ulcerative colitis. Dis", Colon Rectum, 53, pp.1530~1536 (2010)
  71. Man, S. M., "Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non-Campylobacter jejuni Campylobacter species", J. Infect. Dis, 202, pp.1855~1865 (2010)
  72. Man, S. M., "Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease", Inflamm. Bowel Dis, 16, pp.1008~1016 (2010)
  73. Mahendran, V., "Prevalence of Campylobacter species in adult Crohn's disease and the preferential colonization sites of Campylobacter species in the human intestine", PLoS One, 6, pp.e25417~ (2011)
  74. Gradel, K. O., "Increased short-and longterm risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis", Gastroenterology, 137, pp.495~501 (2009)
  75. Kaakoush, N. O., "The pathogenic potential of Campylobacter concisus strains associated with chronic intestinal diseases", PLoS One, 6, pp.e29045~ (2011)
  76. Siegesmund, A. M., "Campylobacter jejuni infection of differentiated THP-1 macrophages results in interleukin 1 beta release and caspase-1-independent apoptosis", Microbiology, 150, pp.561~569 (2004)
  77. Sears, C. L., "Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes", Clin. Microbiol. Rev, 22, pp.349~369 (2009)
  78. Prindiville, T. P., "Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease", Emerg. Infect. Dis, 6, pp.171~174 (2000)
  79. Rabizadeh, S., "Enterotoxigenic bacteroides fragilis: a potential instigator of colitis", Inflamm. Bowel Dis, 13, pp.1475~1483 (2007)
  80. Mottawea, W., "Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn's disease", Nat. Commun, 7, pp.13419~ (2016)
  81. Linden, D. R., "Endogenous production of H2S in the gastrointestinal tract: still in search of a physiologic function", Antioxid. Redox Signal, 12, pp.1135~1146 (2010)
  82. Cho, I., "Antibiotics in early life alter the murine colonic microbiome and adiposity", Nature, 488, pp.621~626 (2012)
  83. Theriot, C. M., "Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection", Nat. Commun, 5, pp.3114~ (2014)
  84. Sorg, J. A., "Bile salts and glycine as cogerminants for Clostridium difficile spores", J. Bacteriol, 190, pp.2505~2512 (2008)
  85. Buffie, C. G., "Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile", Nature, 517, pp.205~208 (2015)
  86. Hoffmann, T. W., "Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice", ISME J, 10, pp.460~477 (2016)
  87. Eun, C. S., "Induction of bacterial antigenspecific colitis by a simplified human microbiota consortium in gnotobiotic interleukin-10–", – mice, 2014, pp.82, 2239~2246
  88. Palm, N. W., "Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease", Cell, 158, pp.1000~1010 (2014)
  89. Okai, S., "High-affinity monoclonal IgA regulates gut microbiota and prevents colitis in mice", Nat. Microbiol, 1, pp.16103~ (2016)
  90. Nagao-Kitamoto, H., "Functional Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic Mice", Cell Mol. Gastroenterol. Hepatol, 2, pp.468~481 (2016)
  91. Borody, T. J., "Fecal microbiota transplantation and emerging applications", Nat. Rev. Gastroenterol. Hepatol, 9, pp.88~96 (2011)
  92. Khoruts, A., "Understanding the mechanisms of faecal microbiota transplantation", Nat. Rev. Gastroenterol. Hepatol, 13, pp.508~516 (2016)
  93. van, N. E., "Duodenal infusion of donor feces for recurrent Clostridium difficile", N. Engl. J. Med, 368, pp.407~415 (2013)
  94. Hourigan, S. K., "Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease", Aliment. Pharmacol. Ther, 42, pp.741~752 (2015)
  95. Rossen, N. G., "Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis", Gastroenterology, 149, pp.110~118 (2015)
  96. Voitk, A. J., "Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy?", Arch. Surg, 107, pp.329~333 (1973)
  97. Akobeng, A. K., "Enteral nutrition for maintenance of remission in Crohn's disease", Cochrane. Database. Syst. Rev, 18, pp.CD005984~ (2007)
  98. Halmos, E. P., "Diets that differ in their FODMAP content alter the colonic luminal microenvironment", Gut, 64, pp.93~100 (2015)
  99. Croagh, C., "Pilot study on the effect of reducing dietary FODMAP intake on bowel function in patients without a colon", Inflamm. Bowel. Dis, 13, pp.1522~1528 (2007)

이 간행물의 다른 논문 (7건)

The Specific Roles of Vitamins in the Regulation of Immunosurveillance and Maintenance of Immunologic Homeostasis in the GutJun Kunisawa, Koji Hosomipp. 13-19Microbiota Influences Vaccine and Mucosal Adjuvant Efficacy김윤기pp. 20-24Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies천재희, 김덕환pp. 25-40Regulatory Eosinophils in Inflammation and Metabolic Disorders서주영, 양보기, 장명호pp. 41-47Beyond Hygiene: Commensal Microbiota and Allergic Diseases김광순, 홍성욱, Surh Charles D.pp. 48-59
원문 보기